Coronavirus company news summary – Quidel receives funding for assay development – CCMB in India develops low-cost Covid-19 test

12 June 2020 (Last Updated June 12th, 2020 09:38)

Quidel has received funding from the Biomedical Advanced Research and Development Authority (BARDA) to aid in the development of a point-of-care diagnostic assay. This assay will be used to test for SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV). The test will be operated on Quidel’s Sofia 2 flagship instrument.

GeneStore France has announced that its Detection Expert SARS-Cov-2 RT-PCR Test has received approval from CNR France. The test can identify two target regions in the 'N' gene of the RNA genome of the SARS-Cov-2 virus in a multiplex format. The non-pathogen fragments of the viral genome of SARS-Cov-2 are used for a positive control.

India's Centre for Cellular and Molecular Biology (CCMB) researchers have developed a low-cost low-tech PCR (RT-nPCR) test to carry-out SARS-CoV-2 testing. This test is reported to show comparable performance to the typical RT-qPCR test. The Indian Council of Medical Research (ICMR) has released recommendations to only use RT-qPCR test for Covid-19 testing.